ArticleDiscover oncology2026
Derivation and external validation of a prognostic nomogram for human epidermal growth factor receptor 2 negative early young breast cancer in women.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYoung breast cancer (YBC) tends to have more aggressive phenotypes and poorer survival outcomes. This study aimed to derive and validate a prognostic nomogram for human epidermal growth factor receptor 2 (HER2)-negative early YBC.
methodsA total of 7863 patients diagnosed with HER2-negative early YBC between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled. Patients were randomly divided into a training and an internal validation set. To further evaluate the performance of the nomogram, we enrolled patients diagnosed with YBC at Chinese PLA General Hospital using the same inclusion and exclusion criteria. In training set, univariate and multivariate Cox analyses were performed to select independent prognostic factors, which were then used to develop a nomogram to predict the 3- and 5-year overall survival (OS). Calibration curves, concordance index (C-index), receiver operating characteristic curves (ROC), decision curve analysis (DCA) and Kaplan-Meier survival analysis were used to assess the accuracy and clinical utility of the model. The accuracy and predictive ability of the model were confirmed through validation with both the internal and external validation sets.
resultsMultivariate Cox analysis revealed that grade, estrogen receptor, histology, T stage, N stage, and surgery were independent prognostic factors, which were used to construct the nomogram. The C-indexes of the nomogram in the training, internal and external validation sets were 0.739 (95% confidence interval [CI]: 0.723-0.755), 0.748 (95% CI 0.723-0.773) and 0.711 (95% CI 0.573-0.848) respectively. The results of ROC curve analysis indicated good discrimination of the nomogram. Calibration curves revealed the high forecast precision of the nomogram. DCA curves and results of risk stratification showed the clinical usability of the nomogram, with better OS in the low-risk group than in the high-risk group (all P < 0.05).
conclusionsOur prognostic nomogram has good accuracy, forecasting precision, and clinical usability for predicting OS in HER2-negative early YBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.